Video‐urodynamic effects of mirabegron, a β3‐adrenoceptor agonist, in patients with low‐compliance bladder

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 919-8172, Iss. 10, 2015-10 ,pp. : 956-961

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and Safety of the Selective β3‐Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Finding Study

By  

LUTS, Vol. 7, Iss. 2, 2015-05 ,pp. : 84-92

John Wiley & Sons Inc

Access to resources Recommend Favorite

Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3‐adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)

By  

BJU INTERNATIONAL, Vol. 115, Iss. 1, 2015-01 ,pp. : 32-40

John Wiley & Sons Inc

Access to resources Recommend Favorite

Urodynamic Efficacy and Safety of Mirabegron Add‐on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder

By  

LUTS, Vol. 8, Iss. 3, 2016-09 ,pp. : 171-176

John Wiley & Sons Inc

Access to resources Recommend Favorite